摘要
目的为观察绝经后骨质疏松妇女应用益钙宁长期治疗４８周至７２周对骨密度（ＢＭＤ）及骨转换生化指标的影响。方法３３例患者应用益钙宁（２０单位／次，１次／周）加乳酸钙（元素钙，５００ｍｇ／日）治疗，另３５例患者单纯用乳酸钙（元素钙５００ｍｇ／日）治疗。结果应用益钙宁加钙治疗组患者腰椎２～４ＢＭＤ在治疗２４周始即有明显增加并持续至７２周；股骨近端的ＢＭＤ增加，Ｗａｒｄｓ三角区部位见于２４周到４８周；股骨颈部位见于４８周和７２周；大转子部位仅在７２周。血ＢＧＰ水平治疗２４周呈增高的改变，而血ＴＲＡＰ和尿ＨＹＰ／Ｃｒ比值的改变于治疗２４周、４８周和７２周均有明显的下降。单纯用钙对照组于治疗后与治疗前比较未见明显改变。结论本研究结果提示益钙宁长期治疗可抑制骨吸收并可能刺激骨形成。
? Objective To study the changes in bone mineral density and bone turnover in postmenopausal osteoporotic patients treated with Elcatonin. Methods Sixtyeight patients were randomly divided into two groups. In group A, 33 cases were treated with Elcatonin (ECT) 20 u IM each week and calcium (elementary) 500mg/day. In group B, 35 cases were treated with calcium (elementary) 500 mg/day alone. No significant differences were found between the two groups in age, YSM, BMI, and occurrence of bone fracture, BMD in L24, and femoral neck and trochanter. BMD in Ward's triangle was lower in group A than in group B. Results 1. In group A, the percentage changes in the L24 BMD were+3.8%, +4.4% and +5.2%, at 24,48 and 72 weeks after treatment respectively. As compared with Group B, significant BMD increase in the Ward's triangle appeared at 24(+2.7%) and 48(+5.0%) weeks after treatment, but no significant increase was seen at 72 weeks. Significant increase in BMD in femoral neck and trochanter appeared later than in L24, in the former at 48(+4.4%) and 72(+6.2%) weeks, and in the latter at 72(+4.5%) weeks after treatment. No BMD changes were found in group B during the treatment, suggesting a significant difference between group A and group B. 2. The level of serum BGP increased 57.3% in 24 weeks after treatment in group A and the level of serum tartrate resistant acid phosphatase and the ratio of urinary HYP/Cr decreased in 24,48 and 72 weeks after treatment, the decrease rates being -5.7～-10.6% and -5.6～21.3% respectively, which suggested another significant difference between group A and group B. Four patients dropped out due to nausea and headache (2 cases), and moving out of city (2 cases) in group A. Conclusion Longterm treatment of Elcatonin (20 units each week) can prevent bone loss and increase bone mass by inhibiting bone resorption and stimulating bone formation.【
出处
《中华内分泌代谢杂志》
CAS
CSCD
北大核心
1998年第1期29-33,共5页
Chinese Journal of Endocrinology and Metabolism
关键词
益钙宁
绝经后骨质疏松
骨密度
骨转换
Elcatonin
Postmenopausal osteoporosis
Bone mineral density
Bone turnover
